Strides in STXBP1 Research: Feb
What was new in February of 2026
Parkinson’s disease (PD) is the second most common neurodegenerative disorder and is primarily caused by the selective degeneration of dopamine neurons. While several PD-related genes have been discovered, most cases appear to be sporadic, suggesting that the development and progression of the disease likely involve interactions between several genes/proteins. Researchers from Duke University used several advanced genetic tools in living mice to map which proteins interact with three known key Parkinson’s‑related proteins (α‑synuclein, LRRK2, and VPS35), how those proteins are organized inside dopamine neurons, and which ones actually influence neuron survival. Across several experiments, the same theme emerged: proteins that control vesicle trafficking, recycling, and release were consistently disrupted long before neurons began to die. They found that STXBP1, in particular, stood out as a protective factor; when researchers reduced its levels, dopamine neurons became much more vulnerable to toxic α‑synuclein. The study’s findings suggest that early dysfunction of presynaptic proteins is a shared, upstream driver of vulnerability across different genetic forms of Parkinson’s disease, and that stabilizing these vesicle‑handling pathways—potentially including STXBP1—could be a promising direction for early intervention.
Researchers from the Netherlands looked at electroencephalography (EEG) data from 15 children with SNARE-related neurodevelopmental disorders (10 STXBP1 and 5 SYT1 (Synaptotagmin 1)) and compared the data to EEG patterns from a large group of typically developing children. They looked to see how far each STXBP1 or SYT1 child’s brain activity deviated from that of the average typically developing child. They found that larger deviations, especially in slow frequency waves (delta/theta), and how stable the EEG patterns are over time, were linked to more serious disabilities in motor skills, hand use, communication, and adaptive behavior. The approach allowed the team to capture each child’s unique neurophysiological profile despite the small sample size and wide clinical variability. Overall, the work suggests that combining detailed EEG analysis with clinical assessments can provide a more precise picture of disease severity in SNAREopathies and could be used to track progression or treatment effects in the future.
The team at CHOP, the other STARR clinical sites, and the Foundation published a paper describing the protocol for the STARR Natural History Study and a similar study, ProMMiS, for SYNGAP1-RD. The paper discusses the structure and design of both studies and the clinical and parent-reported outcome assessments used to assess individuals with STXBP1-RD or SYNGAP1-RD. The paper also provides some initial analysis of the data to provide evidence that the chosen outcome assessments can reliably be used in these patient populations.
Researchers from the University of Texas, Houston and several other universities looked at communication abilities in 79,518 children with neurodevelopmental disorders and/or autism. They found that different genetic conditions are linked to very different communication abilities. Overall, children with genetic causes of NDDs had much more difficulty with spoken language – they learned words later, used fewer phrases, and had lower expressive and receptive language scores – compared with children who have autism without a known genetic cause. However, some genetic conditions showed relative strengths in nonverbal communication, such as using gestures or expressing feelings. Genetic conditions involving large chromosomal changes (known as copy number variants or CNVs) like 16p11.2 deletion or duplication were associated with relatively strong communication abilities, often better than the autism comparison group, while several single‑gene conditions, especially SCN2A, ASXL3, and STXBP1, showed the most severe challenges across communication measures. Most groups showed gradual improvement in communication with age, but STXBP1 stood out for showing a plateau or decline relative to age expectations, suggesting a risk for developmental stagnation. Overall, the findings highlight that each genetic condition has a distinct communication “fingerprint,” and that speech‑language therapy may be more effective when tailored to the specific strengths and vulnerabilities associated with a child’s genetic diagnosis.
Post-translational modifications (PTMs) are chemical changes that are made to proteins after the protein is made in the cell. These changes can have effects on how the protein functions. A Chinese researcher group showed that one type of PTM, called crotonylation, to the STXBP1 protein can make the brain more likely to have seizures by weakening the function of GABA-releasing inhibitory synapses. In mouse models of temporal lobe epilepsy, the researchers found that crotonylation at one specific spot on the STXBP1 protein disrupts how STXBP1 binds to its partner protein STX1B, which is essential for packaging and releasing inhibitory neurotransmitter vesicles. When this binding is weakened, fewer GABA‑filled vesicles reach the presynaptic terminal, reducing inhibitory signaling and tipping the brain toward hyperexcitability. Mice engineered to mimic this crotonylation showed more frequent and more severe seizures, while blocking crotonyl‑CoA production (the molecule needed for crotonylation) reduced seizure susceptibility. Overall, the study suggests that abnormal crotonylation of STXBP1 is an early driver of epileptogenesis and could be a promising target for new epilepsy treatments.
